The COVID-19 pandemic has spread globally infecting and killing millions. Those with cardiovascular disease (CVD) are at higher risk of increased disease severity and mortality. We performed a systematic review and meta-analysis to estimate the rate of in-hospital mortality following different treatments on COVID-19 in patients with CVD.
Methods
Pertinent articles were identified from the PubMed, Google Scholar, Ovid MEDLINE, and Ovid EMBASE databases. This study protocol was registered under PROSPERO with the identifier CRD42020183057.
Results
Of the 1673 papers scrutinized, 46 were included in the review. Of the 2553 patients (mean age 63.9 ± 2.7 years/o; 57.2% male), the most frequent CVDs were coronary artery disease (9.09%) and peripheral arterial disease (5.4%) and the most frequent cardiovascular risk factors were hypertension (86.7%) and diabetes (23.7%). Most patients were on multiple treatments. 14 COVID-19 treatments were compared with controls. The pooled event rate for in-hospital mortality was 20% (95% confidence interval (CI): 11–33%); certain heterogeneity was observed across studies.
Conclusions
COVID-19 is associated with a high in-hospital mortality rate in patients with CVD. This study shows that previous CVD determines mortality, regardless of the type of COVID-19 administered therapy. Treatments for at-risk patients should be administered carefully and monitored closely until further data are available.
VerityROkellLCDorigattiI, et al.Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis2020; 20: 669–677.
3.
DrigginEMadhavanMVBikdeliB, et al.Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol2020; 75: 2352–2371.
4.
PhuaJWengLLingL, et al.Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Res Med2020; 8: 506–517.
5.
ClerkinKJFriedJARaikhelkarJ, et al.Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation2020; 141: 1648–1655.
6.
ErberJWiessnerJRHuberleC, et al.Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - a case series. Transfus Apher Sci2021: 103278.
7.
SinghSChakravartyTChenP, et al.Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol2020115: 36.
8.
MahajanABhattacharyyaS. A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. Biomed J2021; 44: 63–73.
9.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6: e1000097.
10.
StrouprDFBerlinrJAMortonrSC, et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000; 283: 2008–2012.
11.
InciardiRMAdamoMLupiL, et al.Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J2020; 41: 1821–1829. DOI: 10.1093/eurheartj/ehaa388
12.
FriedJARamasubbuKBhattR, et al.The variety of cardiovascular presentations of COVID-19. Circulation2020; 141: 1930–1936.
13.
ChorinEWadhwaniLMagnaniS, et al.QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm2020; 17: 1425–1433.
14.
BorbaMGSValFFASampaioVS, et al.Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open2020; 3: e208857.
15.
PurohitRKanwalAPanditA, et al.Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19. Am J Case Rep2020; 21: e925554.
16.
BrüggemannRGietemaHJallahB, et al.Arterial and venous thromboembolic disease in a patient with COVID-19: a case report. Thromb Res2020; 191: 153–155.
17.
O’BrienCNingNMcAvoyJ, et al.Electrical storm in COVID-19. JACC Case Rep2020; 2: 1256–1260.
18.
OverstadSTjonnfjordEGarabetL, et al.Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - a report of 4 cases. Thromb Res2020; 194: 116–118.
19.
AsifTKassabKIskanderF, et al.Acute pericarditis and cardiac tamponade in a patient with COVID-19: a therapeutic challenge. Eur J Case Rep Int Med2020; 7: 001701.
20.
SinghRFuentesSEllisonH, et al.Case of hemorrhagic cardiac tamponade in a patient with COVID-19 infection. CASE2020; 4: 316–319.
21.
ToniatiPPivaSCattaliniM, et al.Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev2020; 19: 102568.
22.
MathiesDRauschningDWagnerU, et al.A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant. Am J Transplant2020; 20: 1925–1929.
23.
DongNCaiJZhouY, et al.End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. JACC Heart Fail2020; 8: 515–517.
24.
FerreyAJChoiGHannaRM, et al.A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease. Am J Nephrol2020; 51: 337–342.
25.
RadbelJNarayananNBhattPJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest2020l; 158: e15–e19.
26.
WoehlBLawsonBJambertL, et al.4 cases of aortic thrombosis in patients with COVID-19. JACC Case Rep2020; 2: 1397–1401.
27.
LaxSFSkokKZechnerP, et al.Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Annals Int Med2020; 173: 350–361.
28.
VilaroJAl-AniMManjarresDG, et al.Severe COVID-19 after recent heart transplantation complicated by allograft dysfunction. JACC Case Rep2020; 2: 1347–1350.
29.
WangYJiangWHeQ, et al.A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther2020; 5: 57.
30.
SalaSPerettoGGramegnaM, et al.Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J2020; 41: 1861–1862.
31.
GuoTFanYChenM, et al.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol2020; 5: 811–1818.
32.
DuanKLiuBLiC, et al.Effectiveness of convalescent plasma therapy in severe COVID-19 patients.Proc Natl Acad Sci USA2020; 117: 9490–19496.
33.
GnecchiMMorettiFBassiEM, et al.Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet2020; 395: e116.
34.
ZhangWZhaoYZhangF, et al.The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol2020; 214: 108393.
35.
PericàsJMHernandez-MenesesMSheahanTP, et al.COVID-19: from epidemiology to treatment. Eur Heart J2020; 41: 2092–2112.
36.
SinghSChakravartyTChenP, et al.Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol2020; 115: 36.
37.
Amat-SantosIJSantos-MartinezSLópez-OteroD, et al.Ramipril in high-risk patients with COVID-19. J Am Coll Cardiol2020; 76: 268–276.
38.
HuangLWangYWangL, et al.Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: a case report. Medicine2020; 99: e20956.
39.
SinghRDomenicoCRaoSD, et al.Novel coronavirus disease 2019 in a patient on durable left ventricular assist device support. J Card Fail2020; 26: 438–439.
40.
GaoCGaoCCaiY, et al.Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J2020; 41: 2058–2066.
41.
YanYYangYWangF, et al.Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care2020; 8: e001343.
42.
SakabeMYoshiokaRFujikiA. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases2013; 8: 173–175.
43.
CerielloAStandlECatrinoiuD, et al.Issues of cardiovascular risk management in people with diabetes in the COVID-19 Era. Diabetes Care2020; 43: 1427–1432.
